Core Viewpoint - The National Health Commission has approved a pilot program for internet-based first consultations in pediatric healthcare in Beijing, aiming to leverage information technology to alleviate non-capital functions and meet the medical needs of patients from outside the city [1] Group 1: Pilot Program Details - The pilot will be conducted at Capital Medical University Affiliated Beijing Children's Hospital and Capital Medical University Affiliated Capital Children's Medical Center, focusing on pediatric growth and development, nutrition, and skin diseases [1] - The pilot program is set to last for one year, from January to December 2026, with a requirement for regular progress reports and evaluations [3] Group 2: Regulatory and Operational Requirements - There is an emphasis on regulatory responsibilities, including the use of an internet diagnosis regulatory platform to ensure traceability of medical institutions' operational information, personnel qualifications, and treatment data [2] - Internet diagnosis services must be integrated into a quality control system, ensuring compliance with medical quality, safety regulations, and data security [2] - Medical professionals conducting internet consultations must have appropriate qualifications and at least three years of independent clinical experience, with a "whitelist" management system in place [2] - Guidelines will be established for terminating internet consultations when patients' conditions change or are deemed unsuitable for online treatment, directing them to physical medical institutions [2] - There will be a focus on protecting patient personal information and managing medical data, including monitoring for potential security risks and establishing protocols for handling negative incidents [2]

Core Viewpoint - The company, Lanwei Medical, expects a net profit attributable to shareholders to be between -38 million to -20 million yuan for 2025, with a net profit excluding non-recurring gains and losses projected to be between -55 million to -29 million yuan [1] Group 1: Business Strategy and Operations - The company is actively adapting to national policies and industry trends, optimizing its business structure and upgrading regional integrated operations [1] - Core businesses in medical testing, pathological diagnosis services, and in vitro diagnostic product sales are being strengthened, with ongoing projects like the construction of digital pathology slice labeling standards [1] - A comprehensive medical data management solution covering the entire lifecycle of sample management is being developed, aligning with national health data platform initiatives [1] Group 2: Industry Environment and Challenges - The overall operating environment of the industry is under pressure due to multiple factors, including medical insurance cost control and the expansion of centralized procurement [1] - The company is focusing on optimizing its product and service structure to address the challenges of lower-than-expected business revenue, while increasing investments in digitalization and improving operational efficiency [1] Group 3: Financial Performance and Adjustments - The company has made provisions for credit impairment on accounts receivable in accordance with accounting standards, and has seen positive recovery in some long-aged accounts receivable [1] - Due to intensified competition and strategic abandonment of loss-making businesses, the company is shifting its operational goals from mere scale and revenue growth to a focus on profitability and healthy cash flow [1] - Non-recurring gains and losses are expected to impact the net profit attributable to shareholders by approximately 9 million to 17 million yuan [1]